NSCLC, metastatic
Invited discussant abstracts 1203PD, 1204PD, 1205PD and 1206PD
Date
09 Oct 2016Session
NSCLC, metastaticPresenters
Enriqueta FelipAuthors
E. FelipAuthor affiliations
- Oncologia Médica, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
2041 - LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC)
Presenter: Atsushi Horiike
Session: NSCLC, metastatic
Resources:
Abstract
1608 - Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
Presenter: Vamsidhar Velcheti
Session: NSCLC, metastatic
Resources:
Abstract
1911 - Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study
Presenter: Sun Min Lim
Session: NSCLC, metastatic
Resources:
Abstract
2435 - Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001
Presenter: Alice Shaw
Session: NSCLC, metastatic
Resources:
Abstract
1753 - Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial
Presenter: Lyudmila Bazhenova
Session: NSCLC, metastatic
Resources:
Abstract
2387 - Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
Presenter: Leena Gandhi
Session: NSCLC, metastatic
Resources:
Abstract
3636 - Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Presenter: Leora Horn
Session: NSCLC, metastatic
Resources:
Abstract
Invited discussant abstracts 1207PD, 1209PD and 1210PD
Presenter: Sanjay Popat
Session: NSCLC, metastatic
Resources:
Slides
Webcast
3933 - Cost-effectiveness of KRAS, EGFR and ALK testing for therapeutic decision making of advanced stage non-small cell lung cancer (NSCLC): the French IFCT-PREDICT.amm study
Presenter: A Drezet
Session: NSCLC, metastatic
Resources:
Abstract
2585 - Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)
Presenter: Balazs Halmos
Session: NSCLC, metastatic
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.